First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab

References

• Surveillance Epidemiology and End Results (Seer) cancer statistics review 1975–2006. Bethesda, MA/USA: National Cancer Institute[updated April 2009, cited Oct 2009]. http://seer.cancer.gov/csr/1975_2006/
   Google Scholar
• DighieroGBinetJLWhen and how to treat chronic lymphocytic leukemiaN Engl J Med2000343241799180111114321
   PubMed Web of Science ®Google Scholar
• RozmanCMontserratEChronic lymphocytic leukemiaN Engl J Med199533316105210577675049
   PubMed Web of Science ®Google Scholar
• DohnerHStilgenbauerSBennerAGenomic aberrations and survival in chronic lymphocytic leukemiaN Engl J Med2000343261910191611136261
   PubMed Web of Science ®Google Scholar
• DohnerHStilgenbauerSDohnerKBentzMLichterPChromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysisJ Mol Med199977226628110023780
   PubMed Web of Science ®Google Scholar
• CordoneIMasiSMauroFRp53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosisBlood19989111434243499596683
   PubMed Web of Science ®Google Scholar
• DohnerHFischerKBentzMp53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemiasBlood1995856158015897888675
   PubMed Web of Science ®Google Scholar
• ByrdJCGribbenJGPetersonBLSelect high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapyJ Clin Oncol200624343744316344317
   PubMed Web of Science ®Google Scholar
• CatovskyDRichardsSMatutesEAssessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trialLancet2007370958323023917658394
   PubMed Web of Science ®Google Scholar
• StilgenbauerSKroberABuschR17p Deletion predicts for inferior overall survival after fludarabine-based first line therapy in chronic lymphocytic leukemia: first analysis of genetics in the CLL4 trial of the GCLLSGASH Annual Meeting Abstracts200510611715
   Google Scholar
• KeatingMJO’BrienSKontoyiannisDResults of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemiaLeuk Lymphoma20024391755176212685828
   PubMed Web of Science ®Google Scholar
• AustenBSkowronskaABakerCMutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletionJ Clin Oncol200725345448545717968022
   PubMed Web of Science ®Google Scholar
• DamleRNWasilTFaisFIg V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemiaBlood19999461840184710477712
   PubMed Web of Science ®Google Scholar
• HamblinTJDavisZGardinerAOscierDGStevensonFKUnmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemiaBlood19999461848185410477713
   PubMed Web of Science ®Google Scholar
• CrespoMBoschFVillamorNZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemiaN Engl J Med2003348181764177512724482
   PubMed Web of Science ®Google Scholar
• DighieroGMaloumKDesablensBChlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic LeukemiaN Engl J Med199833821150615149593789
   PubMed Web of Science ®Google Scholar
• HallekMFingerle-RowsonGFinkA-MFirst-Line treatment with tludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): Results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study GroupBlood200911453519451549
   PubMed Web of Science ®Google Scholar
• KeatingMJO’BrienSAlbitarMEarly results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemiaJ Clin Oncol200523184079408815767648
   PubMed Web of Science ®Google Scholar
• TamCSO’BrienSWierdaWLong-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemiaBlood2008112497598018411418
   PubMed Web of Science ®Google Scholar
• BoschFAbrisquetaPVillamorNRituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemiaJ Clin Oncol200927274578458419704063
   PubMed Web of Science ®Google Scholar
• FaderlSWierdaWO’BrienSFerrajoliALernerSKeatingMJFludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL < 70 yearsLeuk Res201034328428819646755
   PubMed Web of Science ®Google Scholar
• FerrajoliAFaderlSO’BrienSExperience with fludarabine, cyclophosphamide, rituximab (FCR) plus GM-CSF in frontline therapy for chronic lymphocytic leukemia (CLL)Blood2008112113173
   Web of Science ®Google Scholar
• FischerKStilgenbauerSSchweighoferCDBendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG)Blood20081121133018451308
   PubMed Web of Science ®Google Scholar
• FoonKABoyiadzisMLandSRChemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemiaJ Clin Oncol200927449850319075274
   PubMed Web of Science ®Google Scholar
• SchletteEAdmirandJWierdaWp53 expression by immunohistochemistry is an important determinant of survival in chronic lymphocytic leukemia patients receiving frontline chemo-immunotherapyLeuk Lymphoma20095010159760519863337
   PubMed Web of Science ®Google Scholar
• StilgenbauerSEichhorstBFBuschRBiologic and Clinical Markers for Outcome after Fludarabine (F) or F Plus Cyclophosphamide (FC) – Comprehensive Analysis of the CLL4 Trial of the GCLLSGBlood200811211208918596229
   PubMed Web of Science ®Google Scholar
• TsimberidouAMTamCAbruzzoLVChemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemiaCancer2009115237338019117034
   PubMed Web of Science ®Google Scholar
• HanTOhtakiKSadamoriNCytogenetic evidence for clonal evolution in B-cell chronic lymphocytic leukemiaCancer Genet Cytogenet19862343213283490904
   PubMedGoogle Scholar
• ShanafeltTDWitzigTEFinkSRProspective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemiaJ Clin Oncol200624284634464117008705
   PubMed Web of Science ®Google Scholar
• StilgenbauerSSanderSBullingerLClonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survivalHaematologica20079291242124517666364
   PubMed Web of Science ®Google Scholar
• BottcherSRitgenMPottCComparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantationLeukemia200418101637164515343348
   PubMed Web of Science ®Google Scholar
• MorenoCVillamorNColomerDClinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemiaBlood2006107114563456916449533
   PubMed Web of Science ®Google Scholar
• RawstronACVillamorNRitgenMInternational standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemiaLeukemia200721595696417361231
   PubMed Web of Science ®Google Scholar
• MoretonPKennedyBLucasGEradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survivalJ Clin Oncol200523132971297915738539
   PubMed Web of Science ®Google Scholar
• HallekMChesonBDCatovskyDGuidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelinesBlood20081111254465456 Erratum in Blood 2008 Dec 15;112(13):5259.18216293
   PubMed Web of Science ®Google Scholar
• ZenzTHabeSDenzelTWinklerDDohnerHStilgenbauerSHow little is too much? p53 inactivation: from laboratory cutoff to biological basis of chemotherapy resistanceLeukemia200822122257225818480836
   PubMed Web of Science ®Google Scholar
• ZenzTKroberASchererKMonoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-upBlood200811283322332918689542
   PubMed Web of Science ®Google Scholar
• EichhorstBFBuschRStilgenbauerSFirst line therapy with fludarabine compared to chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemiaBlood2009114163382339119605849
   PubMed Web of Science ®Google Scholar
• HaleGXiaMQTigheHPDyerMJWaldmannHThe CAMPATH-1 antigen (CDw52)Tissue Antigens19903531181272165283
   PubMed Web of Science ®Google Scholar
• TreumannALifelyMRSchneiderPFergusonMAPrimary structure of CD52J Biol Chem199527011608860997890742
   PubMed Web of Science ®Google Scholar
• HaleGBrightSChumbleyGRemoval of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complementBlood19836248738826349718
   PubMed Web of Science ®Google Scholar
• GilleeceMHDexterTMEffect of Campath-1H antibody on human hematopoietic progenitors in vitroBlood19938238078127687895
   PubMed Web of Science ®Google Scholar
• RossmannEDLundinJLenkeiRMellstedtHOsterborgAVariability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodiesHematol J20012530030611920265
   PubMedGoogle Scholar
• AmbroseLRMorelASWarrensANNeutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumabBlood2009114143052305519638623
   PubMed Web of Science ®Google Scholar
• MoneAPCheneyCBanksALAlemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanismLeukemia200620227227916341049
   PubMed Web of Science ®Google Scholar
• SmolewskiPSzmigielska-KaplonACebulaBProapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cellsLeuk Lymphoma20054618710015621786
   PubMed Web of Science ®Google Scholar
• StanglmaierMReisSHallekMRituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cellsAnn Hematol2004831063464515309525
   PubMed Web of Science ®Google Scholar
• CruzRIHernandez-IlizaliturriFJOlejniczakSCD52 overexpression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphomaLeuk Lymphoma20071248122424243618067019
   PubMed Web of Science ®Google Scholar
• OsterborgAFoaRBezaresRFManagement guidelines for the use of alemtuzumab in chronic lymphocytic leukemiaLeukemia200923111980198819626051
   PubMed Web of Science ®Google Scholar
• KeatingMJFlinnIJainVTherapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international studyBlood200299103554356111986207
   PubMed Web of Science ®Google Scholar
• LundinJOsterborgABrittingerGCAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin’s lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin’s LymphomaJ Clin Oncol19981610325732639779699
   PubMed Web of Science ®Google Scholar
• MontilloMSchinkoetheTElterTEradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcomeCancer Invest200523648849616203656
   PubMed Web of Science ®Google Scholar
• LundinJKimbyEBjorkholmMPhase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)Blood2002100376877312130484
   PubMed Web of Science ®Google Scholar
• MontilloMCafroAMTedeschiASafety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabineHaematologica2002877695700; discussion 700.12091119
   PubMed Web of Science ®Google Scholar
• MontilloMTedeschiAMiqueleizSAlemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemiaJ Clin Oncol200624152337234216618945
   PubMed Web of Science ®Google Scholar
• HaleGRebelloPBrettmanLRBlood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administrationBlood2004104494895515090452
   PubMed Web of Science ®Google Scholar
• StilgenbauerSZenzTWinklerDSubcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study GroupJ Clin Oncol200927243994400119597025
   PubMed Web of Science ®Google Scholar
• OsterborgAFassasASAnagnostopoulosADyerMJCatovskyDMellstedtHHumanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemiaBr J Haematol19969311511538611450
   PubMed Web of Science ®Google Scholar
• HillmenPSkotnickiABRobakTAlemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemiaJ Clin Oncol200725355616562317984186
   PubMed Web of Science ®Google Scholar
• KarlssonCLundinJKimbyEPhase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemiaBr J Haematol20091441788519016731
   PubMed Web of Science ®Google Scholar
• OsterborgADyerMJBunjesDPhase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic LeukemiaJ Clin Oncol1997154156715749193354
   PubMed Web of Science ®Google Scholar
• MouldDRBaumannAKuhlmannJPopulation pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment responseBr J Clin Pharmacol200764327829117506867
   PubMed Web of Science ®Google Scholar
• LozanskiGHeeremaNAFlinnIWAlemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletionsBlood200410393278328114726385
   PubMed Web of Science ®Google Scholar
• OsujiNCDel GiudiceIMatutesEWotherspoonACDeardenCCatovskyDThe efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53Haematologica200590101435143616219582
   PubMed Web of Science ®Google Scholar
• SayalaHAMoretonPKennedyBEradication of minimal residual disease with alemtuzumab in chronic lymphocytic leukemia is associated with prolonged survival and is an appropriate theraputic endpoint for relapsed CLLBlood2007110113114
   Web of Science ®Google Scholar
• KarlssonCNorinSKimbyEAlemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformationLeukemia200620122204220717051245
   PubMed Web of Science ®Google Scholar
• ElterTBorchmannPSchulzHFludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trialJ Clin Oncol200523287024703116145065
   PubMed Web of Science ®Google Scholar
• MauroFRCortelezziAMolicaSEfficacy and safety of a first-line combined therapeutic approach for young cll patients stratified according to the biological prognostic features: first analysis of the GIMEMA multicenter LLC0405 StudyBlood2008112113167
   Web of Science ®Google Scholar
• ElterTJamesRStilgenbauerSChemoimmunotherapy with fludarabine, cyclophosphamide and alemtuzumab (FC-Cam) in patients with relapsed or genetic high-risk CLL: Final analysis of the CLL2L trial of the German CLL Study GroupBlood2009114209
   Web of Science ®Google Scholar
• MontilloMMiqueleizSTedeschiACombined fludarabine, cyclophosphamide, and alemtuzumab (FCC), an active regimen for treated patients with chronic lymphocytic leukemia (CLL)Blood2007110113133
   Web of Science ®Google Scholar
• LepretreSAurranTMaheBImmunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine (F), cyclophosphamide (C) and mabcampath (Cam) (FCCam) in previously untreated patients (pts) with advanced B-chronic lymphocytic leukemia (B-CLL) : experience on safety and efficacy within a randomised multicenter phase III trial of the French Cooperative Group On CLL and WM (FCGCLL/MW) and the “Groupe Ouest-Est d’Etudes Des Leucémies Aigües Et Autres Maladies Du sang” (GOELAMS): CLL2007FMP (for fit medically patients)Blood2009114538
   Web of Science ®Google Scholar
• ClarkeARPurdieCAHarrisonDJThymocyte apoptosis induced by p53-dependent and independent pathwaysNature199336264238498528479523
   PubMed Web of Science ®Google Scholar
• PettittARMatutesEDeardenCResults of the phase II NCRI CLL206 trial of alemtuzumab in combination with high-dose methylprednisolone for high-risk (17p-) CLLHaematologica200994Suppl 2138 abstr. 0351.
   Google Scholar
• WierdaWGObrienSFerrajoliASalvage therapy with combined cyclophosphamide (C), fludarabine (F), alemtuzumab (A), and rituximab (R) (CFAR) for heavily pre-treated patients with CLLBlood200510611719
   Web of Science ®Google Scholar
• WierdaWGO’BrienSFaderlSCombined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLLBlood20061081131
   Web of Science ®Google Scholar
• ParikhSAKeatingMO’BrienSFrontline combined chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab and rituximab (CFAR) in high-risk chronic lymphocytic leukemiaBlood2009114208
   Web of Science ®Google Scholar
• FrankfurtOHamiltonEDuffeySAlemtuzumab and rituximab combination therapy for patients with untreated CLL – a phase II trialBlood2008112112098
   Web of Science ®Google Scholar
• ZentCSCallTGShanafeltTDEarly treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximabCancer200811382110211818759253
   PubMed Web of Science ®Google Scholar
• DyerMJKelseySMMackayHJIn vivo‚ purging’ of residual disease in CLL with Campath-1HBr J Haematol19979736696729207420
   PubMed Web of Science ®Google Scholar
• O’BrienSMKantarjianHMThomasDAAlemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemiaCancer200398122657266314669286
   PubMed Web of Science ®Google Scholar
• WierdaWGKippsTJKeatingMJSelf-Administered, subcutaneous (SQ) alemtuzumab to eliminate residual disease in patients (pts) with CLLBlood2006108112839
   Web of Science ®Google Scholar
• SchweighoferCDRitgenMEichhorstBFConsolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)Br J Haematol20091441959819016732
   PubMed Web of Science ®Google Scholar
• WendtnerCMRitgenMSchweighoferCDConsolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)Leukemia20041861093110115071604
   PubMed Web of Science ®Google Scholar
• FischerKSchweighoferCDRitgenMDose escalation study to evaluate dose limiting toxicity (DLT), maximum tolerated dose (MTD) and safety of alemtuzumab for consolidation therapy in patients with chronic lymphoycytic leukemia: Phase I/II trial of the German CLL Study Group (GCLLSG)Blood2007110112053
   Web of Science ®Google Scholar
• LinTDonohueKLucasMConsolidation therapy with subcutaneous (SC) alemtuzumab results in severe infectious toxicity in previously untreated CLL patients who achieve a complete response (CR) after fludarabine and rituximab (FR) induction therapy: interim safety analysis of the CALGB Study 10101Blood200711011755
   Web of Science ®Google Scholar
• HainsworthJDVazquezERSpigelDRCombination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research NetworkCancer200811261288129518189296
   PubMed Web of Science ®Google Scholar
• RaiKRPetersonBLAppelbaumFRFludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemiaN Engl J Med2000343241750175711114313
   PubMed Web of Science ®Google Scholar
• EichhorstBFBuschRHopfingerGFludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemiaBlood2006107388589116219797
   PubMed Web of Science ®Google Scholar
• FlinnIWNeubergDSGreverMRPhase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997J Clin Oncol200725779379817283364
   PubMed Web of Science ®Google Scholar
• KnaufWULissichkovTAldaoudAPhase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemiaJ Clin Oncol200927264378438419652068
   PubMed Web of Science ®Google Scholar
• RobakTBlonskiJZGora-TyborJCladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2)Blood2006108247347916551966
   PubMed Web of Science ®Google Scholar
• RobakTBlonskiJZKasznickiMComparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1)Med Sci Monit20051110PI71PI7916192912
   PubMed Web of Science ®Google Scholar
• HainsworthJDLitchySBartonJHSingle-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research NetworkJ Clin Oncol20032191746175112721250
   PubMed Web of Science ®Google Scholar
• ChesonBDBennettJMGreverMNational cancer institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatmentBlood19968712499049978652811
   PubMed Web of Science ®Google Scholar